New hope for treating debilitating movements in overlooked patient group
NCT ID NCT06997198
Summary
This study aims to see if a medication called deutetrabenazine can safely and effectively reduce the involuntary movements of tardive dyskinesia in adults with intellectual and developmental disabilities. It will involve 25 participants who will take the medication for 24 weeks. Researchers will also measure if the treatment improves daily activities, quality of life for participants, and reduces stress for their caregivers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals of Cleveland
Cleveland, Ohio, 44106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.